All In Biotech

Drug Trial Radar · NCT06292351

DMB-I in the Treatment of Alzheimer Type Dementia

Multicenter Randomized Double-blind Placebo-controlled Three-arm Parallel-group Clinical Study to Evaluate the Efficacy and Safety of DMB-I in the Treatment of Dementia Associated With Alzheimer's Disease

Last checked: Nov 19, 2026Latest source record: Mar 28, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 133 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

133

Actual

Start

Dec 27, 2023

Primary completion

Jan 13, 2025

Study completion Jan 31, 2025

Sponsor

Lead sponsor
Bigespas LTDIndustry
Sponsor type
Industry
First posted
Mar 5, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 60 years, up to 90 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess the efficacy and safety of DMB-I for the treatment of patients with Alzheimer type dementia.

Conditions

  • Alzheimer Disease
  • Dementia of Alzheimer Type

Interventions

  • DMB-I (Dimebon)Drug

    20 mg 3 times a day, or 10 mg + 10 mg 3 times a day (for DMB-I + Placebo arm)

  • PlaceboOther

    20 mg 3 times a day, or 10 mg + 10 mg 3 times a day (for DMB-I + Placebo arm)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Mean change in Alzheimer's Disease Assessment Scale score after 26 weeks of therapy (Visit 6) compared to baseline (Visit 0) in patients receiving the study drug or placeboTime frame: Baseline (Visit 0) and 26 weeks (Visit 6)

Locations

7 sites in 1 country. Site status is shown where the registry gives one.

  • State autonomous healthcare institution "Transregional Clinical Diagnostic Center"

    Kazan', Russia

  • Federal State Budgetary Institution "Federal center for brain and neurotechnologies" of the Federal Medical and Biological Agency (FSBI "FCBN" of Russia's FMBA)

    Moscow, Russia

  • Federal State Autonomous Educational Institution of Higher Education I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University)

    Moscow, Russia

  • State public healthcare institution Leningrad regional psychoneurologic dispensary

    Roshchino, Russia

  • "Medical Center Nova Vita"

    Rostov-on-Don, Russia

  • Saint Petersburg State budgetary healthcare institution "City Hospital № 40 of Kurortniy district"

    Saint Petersburg, Russia

  • "Centre of evidence-based medicine" LLC

    Yaroslavl, Russia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.